In-Hospital Outcomes and Discharge Medication Use Among Patients With Critical Limb Ischemia Versus Claudication

TY - JOUR

T1 - In-Hospital Outcomes and Discharge Medication Use Among Patients With Critical Limb Ischemia Versus Claudication

AU - Rymer, Jennifer A.

AU - Kennedy, Kevin F.

AU - Lowenstern, Angela M.

AU - Secemsky, Eric A.

AU - Tsai, Thomas T.

AU - Aronow, Herbert D.

AU - Prasad, Anand

AU - Gray, Bruce

AU - Armstrong, Ehrin J.

AU - Rosenfield, Kenneth

AU - Shishehbor, Mehdi H.

AU - Jones, W. Schuyler

N1 - Funding Information: Please note: The American College of Cardiology's NCDR PVI registry is an initiative of the American College of Cardiology Foundation. This research was supported by the American College of Cardiology Foundation's National Cardiovascular Data Registry. Dr. Rymer has received support from the American College of Cardiology, Abbott, and Boston Scientific. Dr. Lowenstern received funding through the National Institutes of Health T-32 training grant 5 T32 HL069749-14. Dr. Secemsky has received institutional research grants from Medtronic, Cook, BD Bard, AstraZeneca, Cardiovascular Systems, Inc., Boston Scientific, and Philips; and is a consultant or speaker for Medtronic, Cardiovascular Systems, Inc., Cook, and Philips. Dr. Prasad has received research funding from ACIST Medical. Dr. Gray is a consultant for Gore. Dr. Armstrong is a consultant for Abbott Vascular, Boston Scientific, Cardiovascular Systems, Intact Vascular, Janssen, Medtronic, and Philips. Dr. Rosenfield has received research or fellowship support from Atrium-Getinge, Inari Medical, National Institutes of Health, Lutonix-BARD, and Boston Scientific; has served on the scientific advisory board for VIVA Physicians and National PERT Consortium; has held consultant or Scientific Advisory Board positions with Abbott Vascular, Access Vascular, Boston Scientific–BTG, Cordis–Cardinal Health, Cook, Eximo, Thrombolex, Surmodics, Volcano/Philips, Amegen, Shockwave, Cruzar, Capture Vascular, Endospan, Magneto, MD Insider, Micell, Silk Road, Summa Therapeutics, Valcare, and University of Maryland; and holds equity with Access Closure, Access Vascular, Capture Vascular, Contego, Cruzar Systems, Endospan, Embolitech, Eximo, JanaCare, PQ Bypass, Primacea, MD Insider, Micell, Shockwave, Silk Road Medical, Summa Therapeutics, Magneto, Valcare, Thrombolex, and VORTEX. Dr. Shishehbor has served on the Scientific Advisory Boards of Medtronic, Abbott Vascular, Phillips, Terumo, and Boston Scientific. Dr. Jones has received research grants from Agency for Healthcare Research and Quality, AstraZeneca, American Heart Association, Bristol-Myers Squibb, Doris Duke Charitable Foundation, and Patient-Centered Outcomes Research Institute; and has received honoraria from Bayer, Bristol-Myers Squibb, and Janssen Pharmaceuticals. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Funding Information: Please note: The American College of Cardiology’s NCDR PVI registry is an initiative of the American College of Cardiology Foundation. This research was supported by the American College of Cardiology Foundation’s National Cardiovascular Data Registry. Dr. Rymer has received support from the American College of Cardiology, Abbott, and Boston Scientific. Dr. Lowenstern received funding through the National Institutes of Health T-32 training grant 5 T32 HL069749-14. Dr. Secemsky has received institutional research grants from Medtronic, Cook, BD Bard, AstraZeneca, Cardiovascular Systems, Inc., Boston Scientific, and Philips; and is a consultant or speaker for Medtronic, Cardiovascular Systems, Inc., Cook, and Philips. Dr. Prasad has received research funding from ACIST Medical. Dr. Gray is a consultant for Gore. Dr. Armstrong is a consultant for Abbott Vascular, Boston Scientific, Cardiovascular Systems, Intact Vascular, Janssen, Medtronic, and Philips. Dr. Rosenfield has received research or fellowship support from Atrium-Getinge, Inari Medical, National Institutes of Health, Lutonix-BARD, and Boston Scientific; has served on the scientific advisory board for VIVA Physicians and National PERT Consortium; has held consultant or Scientific Advisory Board positions with Abbott Vascular, Access Vascular, Boston Scientific–BTG, Cordis–Cardinal Health, Cook, Eximo, Thrombolex, Surmodics, Volcano/Philips, Amegen, Shockwave, Cruzar, Capture Vascular, Endospan, Magneto, MD Insider, Micell, Silk Road, Summa Therapeutics, Valcare, and University of Maryland; and holds equity with Access Closure, Access Vascular, Capture Vascular, Contego, Cruzar Systems, Endospan, Embolitech, Eximo, JanaCare, PQ Bypass, Primacea, MD Insider, Micell, Shockwave, Silk Road Medical, Summa Therapeutics, Magneto, Valcare, Thrombolex, and VORTEX. Dr. Shishehbor has served on the Scientific Advisory Boards of Medtronic, Abbott Vascular, Phillips, Terumo, and Boston Scientific. Dr. Jones has received research grants from Agency for Healthcare Research and Quality, AstraZeneca, American Heart Association, Bristol-Myers Squibb, Doris Duke Charitable Foundation, and Patient-Centered Outcomes Research Institute; and has received honoraria from Bayer, Bristol-Myers Squibb, and Janssen Pharmaceuticals. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

PY - 2020/2/18

Y1 - 2020/2/18

UR - http://www.scopus.com/inward/record.url?scp=85078798553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85078798553&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2019.11.053

DO - 10.1016/j.jacc.2019.11.053

M3 - Letter

C2 - 32057381

AN - SCOPUS:85078798553

SN - 0735-1097

VL - 75

SP - 704

EP - 706

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

IS - 6

ER -